beremagene geperpavec-svdt (Vyjuvek)

Indications

• treatment of wounds in patients age >= 6 months with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

Dosage

• beremagene geperpavec-svdt 5000000000 UNT/ML Topical Suspension [Vyjuvek]

Mechanism of action

• Herpes-simplex type-1 (HSV-1) vector-based genetherapy

More general terms

• gene therapy